Posted by Michael Wonder on 04 Nov 2021
OS Therapies receives rare paediatric disease designation in osteosarcoma for OST-HER2 (Listeria monocytogenes)
3 November 2021 - Pathway to priority review voucher and expedited review by the FDA.
OS Therapies today announced the U.S. FDA has granted rare paediatric disease designation for OST-HER2 (OST31-164) for the treatment of osteosarcoma.
